Position in DNLI
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$441,600
-$2,501,476 QoQ
Shares Held
23,000
-89.1% QoQ
Ownership
0.014%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2022
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026TWINBEECH CAPITAL LP holds $19,348,066 across 17 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AXSM |
Axsome Therapeutics, Inc.
|
18,135 | $4,438,903 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
14,325 | $4,312,254 | |
| 3 | PCVX |
Vaxcyte, Inc.
|
42,192 | $2,452,620 | |
| 4 | INSM |
INSMED Inc
|
13,646 | $1,454,936 | |
| 5 | COGT |
Cogent Biosciences, Inc.
|
31,387 | $1,214,676 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
9,900 | $737,352 | |
| 7 | VERA |
Vera Therapeutics, Inc.
|
16,200 | $695,142 | |
| 8 | CAPR |
Capricor Therapeutics, Inc.
|
28,337 | $682,354 |
All Filings in DNLI
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $441,600 | 23,000 | Shares | Sole | 2026-05-15 | |
| 2025-06-30 | $2,943,076 | 210,370 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $979,139 | 72,022 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $5,188,462 | 254,586 | Shares | Sole | 2025-02-14 | |
| 2024-03-31 | $3,639,509 | 177,364 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $870,846 | 40,580 | Shares | Sole | 2024-02-14 | |
| 2023-03-31 | $3,439,918 | 149,302 | Shares | Sole | 2023-05-15 | |
| 2022-03-31 | $580,539 | 18,046 | Shares | Sole | 2022-05-16 | |
| No filing history on record for this holder in this stock. | ||||||